A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants
Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Part C of the study includes only Japanese and Chinese participants * Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive Exclusion Criteria: * Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy * Have a significant history or current thyroid disease * Have a significant history of or current psychiatric disorders, rheumato…
Interventions
- DrugLY3867070
Administered orally
- DrugPlacebo
Administered orally
Locations (2)
- Anaheim Clinical Trials, LLCAnaheim, California
- Fortrea Clinical Research UnitDallas, Texas